Goldman analyst Isaac Ro raised the Life Science Tools sector to Attractive from Neutral and upgraded FEI Company to Buy and increased his price target to $94 from $73 on shares. Ro said most key end markets are poised to accelerate, offering modest upside to consensus estimates, and FEI Company offers ample balance sheet flexibility and long-term TAM expansion that appears to be unappreciated. FEI Company is also a takeout target given its leading technology profile and trends towards consolidation in both Life Science Tools and Semi end markets, Ro commented.